BackTable / VI / Podcast / Episode #67

Locoregional Therapies for Bridging to Transplant in HCC

with Dr. Alex Kim

Interventional Radiologist Dr. Alex Kim and Dr. Christopher Beck discuss the utility of different locoregional liver therapies in bridging HCC patients to transplant.

Sponsored by:

TriSalus Life Sciences
Locoregional Therapies for Bridging to Transplant in HCC with Dr. Alex Kim on the BackTable VI Podcast)
Ep 67 Locoregional Therapies for Bridging to Transplant in HCC with Dr. Alex Kim
00:00 / 01:04

BackTable, LLC (Producer). (2020, June 8). Ep. 67 – Locoregional Therapies for Bridging to Transplant in HCC [Audio podcast]. Retrieved from https://www.backtable.com

BackTable CMEfy button

Stay Up To Date

Follow:

Subscribe:

Sign Up:

Podcast Contributors

Dr. Alex Kim discusses Locoregional Therapies for Bridging to Transplant in HCC on the BackTable 67 Podcast

Dr. Alex Kim

Dr. Alex Kim is a practicing Interventional Radiologist at MedStar Georgetown University Hospital in Washington D.C.

Dr. Christopher Beck discusses Locoregional Therapies for Bridging to Transplant in HCC on the BackTable 67 Podcast

Dr. Christopher Beck

Dr. Chris Beck is a practicing interventional radiologist with Regional Radiology Group in New Orleans.

Show Notes

Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693‐699. doi:10.1056/NEJM199603143341104 - Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394‐1403. doi:10.1053/jhep.2001.24563 - Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival

DiNorcia J, Florman SS, Haydel B, et al. Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium. Ann Surg. 2020;271(4):616‐624. doi:10.1097/SLA.0000000000003253 - Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma

Shi L, Wang J, Ding N, et al. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nat Commun. 2019;10(1):5421. Published 2019 Nov 28. doi:10.1038/s41467-019-13204-3 - Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy

Kim AY, Miller A. Evaluation of Surefire's precision direct-to-tumor embolization device to augment therapeutic response to intra-arterial, liver-directed therapies for patients with primary and secondary liver cancers. Expert Rev Med Devices. 2016;13(5):435‐443. doi:10.1586/17434440.2016.1164594

Kim AY, Frantz S, Krishnan P, et al. Short-term imaging response after drug-eluting embolic trans-arterial chemoembolization delivered with the Surefire Infusion System® for the treatment of hepatocellular carcinoma. PLoS One. 2017;12(9):e0183861. Published 2017 Sep 1. doi:10.1371/journal.pone.0183861

Cheng A-L, Qin S, Ikeda M, et al. IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).Ann Oncol. 2019;30(suppl 9):ix186-ix187. doi: 10.1093/annonc/mdz446.002. - IMbrave150: efficacy and safety results

National Comprehensive Cancer Network: https://www.nccn.org/

Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734-9. - Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma

Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164-71. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

Earn CME When You Listen to BackTable CMEfy

Up Next

Y90 in the OBL with Dr. Jayson Brower on the BackTable VI Podcast)
Cholecystostomy Tubes with Dr. Christopher Beck on the BackTable VI Podcast)
Discussing the Complications Survey Results with the BackTable Team on the BackTable VI Podcast)
Mediport Placement with Dr. Christopher Beck and Dr. Aaron Fritts on the BackTable VI Podcast)
Road to Becoming a Y90 Authorized User (While in Training!) with Dr. Rakesh Ahuja on the BackTable VI Podcast)
New Tools to Treat Severe Distal Femoropopliteal Disease with Dr. John Rundback on the BackTable VI Podcast)

Articles

Topics

Hepatocellular Carcinoma Condition Overview
TACE Procedure Steps & Treatment
Y90 Radioembolization Procedure Prep

Get in touch!

We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.

Select which show(s) you would like to subscribe to:

Thanks! Message sent.